Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. LPCN
stocks logo

LPCN

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
116.00K
-96.68%
-0.610
-284.85%
100.00K
+6.54%
-0.600
+71.43%
--
--
-0.610
+48.78%
Estimates Revision
The market is revising Downward the revenue expectations for Lipocine Inc. (LPCN) for FY2025, with the revenue forecasts being adjusted by -1.68% over the past three months. During the same period, the stock price has changed by 7.27%.
Revenue Estimates for FY2025
Revise Downward
down Image
-1.68%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-0.25%
In Past 3 Month
Stock Price
Go Up
up Image
+7.27%
In Past 3 Month
Wall Street analysts forecast LPCN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LPCN is 6.88 USD with a low forecast of 6.75 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast LPCN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LPCN is 6.88 USD with a low forecast of 6.75 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.100
sliders
Low
6.75
Averages
6.88
High
7.00
Current: 3.100
sliders
Low
6.75
Averages
6.88
High
7.00
H.C. Wainwright
H.C. Wainwright
Buy -> Buy
downgrade
$8 -> $7
2025-11-13
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$8 -> $7
2025-11-13
downgrade
Buy -> Buy
Reason
H.C. Wainwright lowered the firm's price target on Lipocine to $7 from $8 and keeps a Buy rating on the shares following the Q3 report.
H.C. Wainwright
Yi Chen
initiated
$8
2025-05-29
Reason
H.C. Wainwright
Yi Chen
Price Target
$8
2025-05-29
initiated
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Lipocine Inc (LPCN.O) is -1.30, compared to its 5-year average forward P/E of -4.81. For a more detailed relative valuation and DCF analysis to assess Lipocine Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.81
Current PE
-1.30
Overvalued PE
-1.70
Undervalued PE
-7.92

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.08
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.36
Undervalued EV/EBITDA
-0.19

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
17.23
Current PS
0.00
Overvalued PS
35.60
Undervalued PS
-1.14
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

LPCN News & Events

Events Timeline

(ET)
2025-11-18
09:36:50
Lipocine announces 'encouraging' safety results in Phase 3 trial of LPCN 1154
select
2025-11-06 (ET)
2025-11-06
08:02:47
Lipocine Announces Q3 Earnings Per Share of 59 Cents, Up from 44 Cents Last Year
select
2025-09-30 (ET)
2025-09-30
08:07:47
Lipocine Offers Update on Phase 3 Clinical Trial for Postpartum Depression
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
11-18PRnewswire
Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

  • Clinical Trial Update: Lipocine Inc. announced that the independent Data Safety Monitoring Board (DSMB) has reviewed its Phase 3 clinical trial for LPCN 1154, an oral treatment for postpartum depression (PPD), and recommended that the trial continue as planned without modifications.

  • Safety Profile: Over half of the planned participants have completed dosing with no serious adverse events, dose reductions, or reports of excessive sedation, indicating a favorable safety profile for LPCN 1154.

  • Expected Results Timeline: Topline results from the trial are anticipated in the second quarter of 2026, with an interim DSMB meeting and safety update expected in early 2026.

  • Product Overview: LPCN 1154 aims to provide rapid relief for PPD with a favorable tolerability profile, potentially becoming a first-line treatment option for women experiencing severe PPD.

[object Object]
Preview
9.5
11-06PRnewswire
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025

  • Financial Results: Lipocine Inc. reported a net loss of $3.2 million for Q3 2025, with total revenues of $114,574, a significant decrease from $7.7 million in the same period in 2024. The company had $15.1 million in cash and equivalents as of September 30, 2025.

  • LPCN 1154 for Postpartum Depression: The Phase 3 trial for LPCN 1154, an oral treatment for postpartum depression, is ongoing, with top-line data expected in Q2 2026. A safety update will follow a review by the Data Safety Monitoring Board in November 2025.

  • LPCN 2101 for Epilepsy: Lipocine is considering a Phase 2 study for LPCN 2101, a treatment for epilepsy, and has two abstracts accepted for presentation at the upcoming American Epilepsy Society meeting in December 2025.

  • LPCN 2401 for Obesity Management: The company is exploring a Phase 2 study for LPCN 2401, aimed at obesity management, and is also looking for potential partnerships for commercialization of its drug candidates, including LPCN 1154 and LPCN 2401.

[object Object]
Preview
9.0
11-04PRnewswire
Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek®

  • LPCN 2401 Presentation: Lipocine Inc. presented data at the ObesityWeek annual meeting, showcasing that LPCN 2401 significantly improves body composition and liver health in men with obesity over a 20-week Phase 2 trial.

  • Trial Results: The trial demonstrated that LPCN 2401 increased lean mass and reduced fat mass, with notable improvements in liver health markers observed as early as 4 to 8 weeks into treatment.

  • Safety and Tolerability: LPCN 2401 was well tolerated throughout the study, with no significant safety concerns reported over 72 weeks of exposure.

  • Company Overview: Lipocine is focused on developing innovative oral delivery biopharmaceuticals, with multiple candidates in various stages of development targeting significant medical needs, including obesity management and liver health.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Lipocine Inc (LPCN) stock price today?

The current price of LPCN is 3.1 USD — it has increased 0.32 % in the last trading day.

arrow icon

What is Lipocine Inc (LPCN)'s business?

Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics. The Company’s clinical development candidates include: LPCN 1154, oral brexanolone, for the treatment of postpartum depression, LPCN 2101, for the treatment of epilepsy, LPCN 2203, an oral candidate targeted for the management of essential tremor, LPCN 2401, an oral proprietary anabolic androgen receptor agonist for improved body composition in obesity management, and LPCN 1148, for the management of decompensated cirrhosis. It is also developing LPCN 1107, for the prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, and LPCN 1144, for the treatment of metabolic dysfunction-associated steatohepatitis. Its product candidate, TLANDO, is a novel oral prodrug of testosterone containing testosterone undecanoate developed by the Company.

arrow icon

What is the price predicton of LPCN Stock?

Wall Street analysts forecast LPCN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LPCN is 6.88 USD with a low forecast of 6.75 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Lipocine Inc (LPCN)'s revenue for the last quarter?

Lipocine Inc revenue for the last quarter amounts to 114.57K USD, decreased % YoY.

arrow icon

What is Lipocine Inc (LPCN)'s earnings per share (EPS) for the last quarter?

Lipocine Inc. EPS for the last quarter amounts to -0.59 USD, increased 43.90 % YoY.

arrow icon

What changes have occurred in the market's expectations for Lipocine Inc (LPCN)'s fundamentals?

The market is revising Downward the revenue expectations for Lipocine Inc. (LPCN) for FY2025, with the revenue forecasts being adjusted by -1.68% over the past three months. During the same period, the stock price has changed by 7.27%.
arrow icon

How many employees does Lipocine Inc (LPCN). have?

Lipocine Inc (LPCN) has 16 emplpoyees as of December 05 2025.

arrow icon

What is Lipocine Inc (LPCN) market cap?

Today LPCN has the market capitalization of 17.21M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free